CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −300 | $30.73 | $9K | 24,353 |
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −25,000 | 43,134 | ||
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −15,000 | 35,000 | ||
| 2026-05-26 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +60,000 | $10.00 | $600K | 84,353 |
| 2026-05-26 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +5,000 | $10.90 | $55K | 89,353 |
| 2026-05-26 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −65,000 | $35.69 | $2.3M | 24,353 |
| 2026-05-26 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −60,000 | 80,015 | ||
| 2026-05-26 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −5,000 | 68,134 | ||
| 2026-03-11 | LANGE LOUIS G Director | Sale | −44,173 | $30.41 | $1.3M | 10,806 |
| 2026-03-11 | LANGE LOUIS G Director | Sale | −446 | $31.23 | $14K | 10,360 |
| 2026-03-09 | LANGE LOUIS G Director | Option exercise | +44,619 | $11.50 | $513K | 54,979 |
| 2026-03-09 | LANGE LOUIS G Director | Option exercise · Warrant (right to buy) | −44,619 | 0 | ||
| 2026-03-09 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise 10b5-1 | +101,409 | 170,711 | ||
| 2026-03-09 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −101,409 | $30.29 | $3.1M | 69,302 |
| 2026-03-09 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise · Option (right to buy) 10b5-1 | −101,409 | 520,229 | ||
| 2026-03-06 | LANGE LOUIS G Director | Sale | −28,186 | $29.41 | $829K | 0 |
| 2026-03-06 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise 10b5-1 | +94,124 | 163,426 | ||
| 2026-03-06 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −94,124 | $30.32 | $2.9M | 69,302 |
| 2026-03-06 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise · Option (right to buy) 10b5-1 | −94,124 | 621,638 | ||
| 2026-03-05 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise 10b5-1 | +104,467 | 173,769 |
Page 2 of 15 · 300 trades